WithdrawnPhase 2NCT03438344
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
Studying Acute myeloid leukemia with t(9;22)(q34.1;q11.2)
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- City of Hope Medical Center
- Principal Investigator
- Ryotaro Nakamura, MD, MDCity of Hope Medical Center
- Intervention
- Multi-antigen CMV-Modified Vaccinia Ankara Vaccine(biological)
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2021
Study locations (3)
- City of Hope Medical Center, Duarte, California, United States
- Northside Hospital, Atlanta, Georgia, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03438344 on ClinicalTrials.govOther trials for Acute myeloid leukemia with t(9;22)(q34.1;q11.2)
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT05031897Two Step Haplo With Radiation ConditioningThomas Jefferson University
- ACTIVE NOT RECRUITINGPHASE2NCT04188405Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous LeukemiaM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE1NCT02530034Hu8F4 in Treating Patients With Advanced Hematologic MalignanciesM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT03630991Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing ChemotherapyM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT03147612Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT02861417Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell TransplantM.D. Anderson Cancer Center
See all trials for Acute myeloid leukemia with t(9;22)(q34.1;q11.2) →